**Additional file Table S1. Baseline characteristics of patients in the RPV, EFV and boosted PI groups**

|  |  |  |  |
| --- | --- | --- | --- |
|  | ABC/3TC/RPV (n=66) (%) | ABC/3TC/EFV (n=89) (%) | ABC/3TC/boosted PIs (n=15) (%) |
| Age, years, median (IQR) | 35 (28-46) | 39 (30-49) | 35 (28-47) |
| Male | 63 (95.4) | 81 (91.0) | 14 (93.3) |
| Race Chinese Malay Indian Others | 45 (68.2)16 (24.2)5 (7.5)0 (0) | 62 (69.7)18 (20.2)5 (5.6)4 (4.5) | 11 (73.3)3 (20.0)0 (0)1 (6.7) |
| HIV transmission route Homosexual Heterosexual Bisexual IVDU + Sexual contact Others | 42 (63.6)12 (18.2)8 (12.1)2 (3.0)2 (3.0) | 45 (50.6)26 (29.2)16 (18.0)1 (1.1)1 (1.1) | 9 (60.0)4 (26.7)2 (13.3)0 (0)0 (0) |
| Baseline viral load (copies/ml)  <10,000 10,000 – 50,000 >50,000 | 21 (31.8)34 (51.5)11 (16.7) | 18 (20.2)54 (60.7)17 (19.1) | 6 (40.0)4 (26.7)5 (33.3) |
| Baseline CD4 count 200-350 >350-500 >500 | 21 (31.8)21 (31.8)24 (36.4) | 38 (42.7)26 (29.2)25 (28.1) | 6 (40.0)4 (26.7)5 (33.3) |
| AIDS defining illness  | 0 (0) | 0 (0) | 0 (0) |
| HCV co-infection  | 2 (3.0) | 3 (3.4) | 0 (0) |
| Genotype test at diagnosis  | 29 (44.0) | 46 (51.7) | 9 (60.0) |
| Time from diagnosis to treatment, days, median (IQR) | 67 (45-215) | 48 (85-448) | 33 (73-206) |
| HLA B\*5701 Positive Negative Not done | 0 (0)61 (92.4)5 (7.6) | 1 (1.1)52 (58.4)36 (40.4) | 0 (0)13 (86.7)2 (13.3) |
| Comorbidities Diabetes mellitus Hypertension Hyperlipidemia IHD/CAD Congestive cardiac failure Chronic liver disease Chronic kidney disease Cancer CVA Osteoporosis | 5 (7.5)7 (10.6)5 (7.6)1 (1.5)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0) | 5 (5.6)9 (10.1)9 (10.1)2 (2.2)0 (0)0 (0)2 (2.2)1 (1.1)0 (0)0 (0) | 1 (6.7)0 (0)0 (0)0 (0)0 (0)0 (0)1 (6.7)0 (0)0 (0)0 (0) |

ABC: Abacavir; 3TC: Lamivudine; RPV: Rilpivirine; IQR: Interquartile Range; IVDU: Intravenous Drug Use; AIDS: Acquired Immunodeficiency Syndrome; HCV: Hepatitis C Virus; IHD: Ischaemic Heart Disease; CAD: Coronary Artery Disease; CVA: Cerebrovascular Accident